South Koreans cross border to Japan for cheaper weight-loss drug

South Korean consumers are traveling to Japan to purchase Mounjaro at a fraction of the price charged in their home country, taking advantage of substantial price disparities between the two markets. The drug, which contains tirzepatide and was originally developed for diabetes treatment, has gained popularity globally as a weight-loss medication due to its appetite-suppressing effects.

The price difference reflects regulatory and healthcare system variations between the nations. In South Korea, Mounjaro carries a premium cost as a relatively new treatment option, while Japanese pricing remains considerably lower. This gap has created an informal cross-border market, with individuals purchasing multiple doses during trips to Japan and transporting them home for personal use.

The trend highlights broader concerns about medication affordability and access across Asia. While Mounjaro's weight-loss applications have generated significant demand, particularly among affluent consumers, pricing structures vary widely by country and healthcare system. South Korean health authorities have not issued specific restrictions on personal importation of the medication for individual consumption.

The phenomenon underscores growing consumer awareness of price variations in pharmaceutical markets and the lengths individuals will undertake to access treatments at lower costs. Similar cross-border medication shopping patterns have emerged in other regions where price differences between neighboring markets are pronounced.